Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Pushing through it at a higher dose usually deepens the problem rather than solving it, because you are leaning harder on receptors that are already turned down
Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
With needleless systems, the stress and anxiety often associated with injections can be significantly reduced, potentially improving treatment adherence and health outcomes
Freezing optimally preserves peptide stability for extended periods
